Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma

Endocrine-Related Cancer

Volumn 20, Issue 4, 2013, Pages 611-619

  Rodriǵuez Antona, Cristina ^a,b   Muñoz Repeto, Iván ^c   Inglada Peŕez, Lucia ^a,b   De Cubas, Aguirre A ^a   Mancikova, Veronika ^a   Canãmero, Marta ^a   Maliszewska, Agnieszka ^a   Gómez, Álvaro ^a   Letón, Rocío ^a   Leandro Garciá, Luis J ^a   Comino Méndez, Iñaki ^a   Sanchez, Lara ^a   Aĺvarez Escolá, Cristina ^d   Aller, Javier ^e   Cascoń, Alberto ^a,b   Robledo, Mercedes ^a,b  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

EGFR; KIT; Medullary thyroid carcinoma; MET; PDGFRB; RMET mutation; Tyrosine kinase inhibitors; VEGF; VEGFR1; VEGFR2; VEGFR3

Indexed keywords

PEPTIDES AND PROTEINS; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KIT; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RET GENE; SCHOOL CHILD; THYROID MEDULLARY CARCINOMA;

EGFR; KIT; MEDULLARY THYROID CARCINOMA; MET; PDGFRB; RET MUTATION; TYROSINE KINASE INHIBITORS; VEGF; VEGFR1; VEGFR2; VEGFR3;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; EXONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PROTO-ONCOGENE PROTEINS C-MET; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; THYROID NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84882760021     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0316     Document Type: Article

References (29)

1. Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R & Nutting CM 2011 Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. European Journal of Endocrinology 165 315-322. (doi:10.1530/EJE-11- 0129)
2. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A et al. 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinology and Metabolism 86 5658-5671. (doi:10.1210/jc.86.12.5658)
3. Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L & Maia AL 2010 Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 20 863-871. (doi:10.1089/thy.2009.0417)
4. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE & Martins RG 2010 Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clinical Cancer Research 16 5260-5268. (doi:10.1158/1078-0432.CCR-10-0994)
5. Cascon A, Ruiz-Llorente S, Rodriguez-Perales S, Honrado E, Martinez-Ramirez A, Leton R, Montero-Conde C, Benitez J, Dopazo J, Cigudosa JC et al. 2005 A novel candidate region linked to development of both pheochromocytoma and head/neck paraganglioma. Genes, Chromosomes & Cancer 42 260-268. (doi:10.1002/gcc.20139)
6. Ceccherini I, Bocciardi R, Luo Y, Pasini B, Hofstra R, Takahashi M & Romeo G 1993 Exon structure and flanking intronic sequences of the human RET proto-oncogene. Biochemical and Biophysical Research Communications 196 1288-1295. (doi:10.1006/bbrc.1993.2392)
7. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P et al. 2008 Axitinib is an active treatment for allhistologic subtypes of advanced thyroid cancer: results from a phase II study. Journal of Clinical Oncology 26 4708-4713. (doi:10.1200/JCO.2007.15.9566)
8. Cote GJ & Gagel RF 2003 Lessons learned from the management of a rare genetic cancer. New England Journal of Medicine 349 1566-1568. (doi:10.1056/NEJMe038148)
9. Duncan TJ, Al-Attar A, Rolland P, Scott IV, Deen S, Liu DT, Spendlove I & Durrant LG 2008 Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clinical Cancer Research 14 3030-3035. (doi:10.1158/1078-0432.CCR-07-1888)
10. Giraudet AL, Vanel D, Leboulleux S, Auperin A, Dromain C, Chami L, Ny Tovo N, Lumbroso J, Lassau N, Bonniaud G et al. 2007 Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. Journal of Clinical Endocrinology and Metabolism 92 4185-4190. (doi:10.1210/jc.2007-1211)
11. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK et al. 2011 Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. Journal of Clinical Endocrinology and Metabolism 96 997-1005. (doi:10.1210/jc.2010-1899)
12. de Hoon MJ, Imoto S, Nolan J & Miyano S 2004 Open source clustering software. Bioinformatics 20 1453-1454. (doi:10.1093/bioinformatics/bth078)
13. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F et al. 2011 Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. Journal of Clinical Oncology 29 2660-2666. (doi:10.1200/JCO. 2010.32.4145)
14. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV et al. 2010 Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. Journal of Clinical Oncology 28 2323-2330. (doi:10.1200/JCO.2009.25.0068)
15. Lee JC, Li CF, Fang FM, Wang JW, Jeng YM, Yu SC, Lin YT, Wu JM, Tsai JW, Li SH et al. 2010 Prognostic implication of MET overexpression in myxofibrosarcomas: an integrative array comparative genomic hybridization, real-time quantitative PCR, immunoblotting, and immunohistochemical analysis. Modern Pathology 23 1379-1392. (doi:10.1038/modpathol.2010.128)
16. Maderna E, Salmaggi A, Calatozzolo C, Limido L & Pollo B 2007 Nestin, PDGFRβ, CXCL12 and VEGF in glioma patients: different profiles of (pro-angiogenic) molecule expression are related with tumor grade and may provide prognostic information. Cancer Biology & Therapy 6 1018-1024. (doi:10.4161/cbt.6.7.4362)
17. Miliaras D, Karasavvidou F, Papanikolaou A & Sioutopoulou D 2004 KIT expression in fetal, normal adult, and neoplastic renal tissues. Journal of Pathology 57 463-466. (doi:10.1136/jcp.2003.013532)
18. Nagy R, Sweet K & Eng C 2004 Highly penetrant hereditary cancer syndromes. Oncogene 23 6445-6470. (doi:10.1038/sj.onc.1207714)
19. Randolph GW & Maniar D 2000 Medullary carcinoma of the thyroid. Cancer Control 7 253-261. (Pubitemid 30387661)
20. Robinson BG, Paz-Ares L, Krebs A, Vasselli J & Haddad R 2010 Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 95 2664-2671. (doi:10.1210/jc.2009-2461)
21. Rodriguez-Antona C, Pallares J, Montero-Conde C, Inglada-Perez L, Castelblanco E, Landa I, Leskela S, Leandro-Garcia LJ, Lopez-Jimenez E, Leton R et al. 2010 Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocrine-Related Cancer 17 7-16. (doi:10.1677/ERC-08-0304)
22. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP et al. 2009 Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. Journal of Clinical Oncology 27 3794-3801. (doi:10.1200/JCO.2008.18.7815)
23. Schoffski P, Elisei R, Müller S, Brose MS, Shah MH, Licitra LF, Jarzab B, Medvedev V, Kreissl M, Niederle B et al. 2013 An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. Journal of Clinical Oncology 31 412-419. (doi:10.1200/JCO.2012.45.0494)
24. Schuffenecker I, Virally-Monod M, Brohet R, Goldgar D, Conte-Devolx B, Leclerc L, Chabre O, Boneu A, Caron J, Houdent C et al. 1998 Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs a Calcitonine. Journal of Clinical Endocrinology and Metabolism 83 487-491. (doi:10.1210/jc.83.2.487)
25. Thornton K, Kim G, Maher VE, Chattopadhyay S, Tang S, Moon YJ, Song P, Marathe A, Balakrishnan S, Zhu H et al. 2012 Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and drug administration drug approval summary. Clinical Cancer Research 18 3722-3730. (doi:10.1158/1078-0432.CCR-12-0411)
26. Uchino S, Noguchi S, Yamashita H, Sato M, Adachi M, Yamashita H, Watanabe S, Ohshima A, Mitsuyama S, Iwashita T et al. 1999 Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type. Japanese Journal of Cancer Research 90 1231-1237. (doi:10.1111/j.1349-7006.1999.tb00701.x)
27. Wells SA Jr, Baylin SB, Johnsrude IS, Harrington DP, Mendelsohn G, Ontjes DJ & Cooper CW 1982 Thyroid venous catheterization in the early diagnosis of familial medullary thyroid carcinoma. Annals of Surgery 196 505-511. (doi:10.1097/00000658-198211000-00001)
28. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J & Schlumberger M 2010 Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. Journal of Clinical Oncology 28 767-772. (doi:10.1200/JCO.2009.23.6604)
29. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR et al. 2012 Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology 30 134-141. (doi:10.1200/JCO.2011.35.5040)